Latest News and Press Releases
Want to stay updated on the latest news?
-
HONG KONG, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced...
-
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib...
-
New York, NY, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Westin Acquisition Corp (NASDAQ): WSTNU, the “Company”), a Cayman Islands exempted company, announced that holders of its 5,750,000 units sold in the...
-
New York, N.Y., Dec. 31, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company...
-
Tel Aviv, Israel, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company strategically pivoting into homeland...
-
CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company....
-
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now...
-
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
-
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla...
-
Nutriband New Year Letter to Shareholders